This multicenter, randomized, double-blind, placebo-controlled, active-referenced
(duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of …

The efficacy of vortioxetine 10 and 20 mg/d vs. placebo on cognitive function and depression
in adults with recurrent moderate-to-severe major depressive disorder (MDD) was …

Background: Management of cognitive deficits in Major Depressive Disorder (MDD) remains
an important unmet need. This meta-analysis evaluated the effects of vortioxetine on …

Abstract Vortioxetine (Brintellix®; Trintellix®), a generally efficacious and well tolerated
antidepressant agent, is approved in the EU and USA for the treatment of major depressive …

Background: These post hoc analyses evaluated vortioxetine efficacy on cognitive
dysfunction in depression. Data were from a double-blind, randomized, fixed-dose, placebo …

Background: This 8-week, randomized, double-blind, placebo-controlled study, conducted
August 2010-May 2012 in the United States, evaluated the safety and efficacy of vortioxetine …

Abstract Background Major Depressive Disorder (MDD) is a complex disease characterized
by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine …

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major
depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5 …

Abstract Background Major Depressive Disorder (MDD) is a heterogeneous disease
characterized by emotional, physical and cognitive symptoms. This study explored the …

Abstract Objective: Vortioxetine (Lu AA21004) is an investigational antidepressant. In vitro
studies indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5 …